4-(4-吗啉基甲基)苯腈 | 37812-51-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(4-吗啉基甲基)苯腈
• 中文别名: 4-吗啉甲基苯甲腈
• 英文名称: 4-(morpholin-4-ylmethyl)benzonitrile
• 英文别名: 4-(morpholinemethyl)benzonitrile；4-(morpholinomethyl)benzonitrile；N-(4-cyanobenzyl)morpholine；4-morpholin-4-ylmethyl-benzonitrile；4-(morpholin-4-ylmethyl)-benzonitrile；p-morpholinomethylbenzonitrile
• CAS: 37812-51-4
• 化学式: C₁₂H₁₄N₂O
• mdl: MFCD00454271
• 分子量: 202.256
• InChiKey: BCZLYNFDOJXWGN-UHFFFAOYSA-N

物化性质

• 熔点：
  84-89°C
• 沸点：
  332.4±32.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  36.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• 包装等级：
  III
• 危险类别：
  8,6.1
• 危险性防范说明：
  P261,P280,P301+P310,P305+P351+P338,P310
• 危险品运输编号：
  2923
• 危险性描述：
  H301,H314
• 储存条件：
  存放于阴凉干燥处。

SDS

Name:	4-(Morpholinomethyl)benzonitrile Material Safety Data Sheet
Synonym:
CAS:	37812-51-4

Section 1 - Chemical Product MSDS Name:4-(Morpholinomethyl)benzonitrile Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
37812-51-4	4-(Morpholinomethyl)benzonitrile	97+%	unlisted

Hazard Symbols: C
Risk Phrases: 20/21/22 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed. Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Harmful if absorbed through the skin. Causes skin burns.
Ingestion:
Harmful if swallowed. Causes gastrointestinal tract burns.
Inhalation:
Harmful if inhaled. Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 37812-51-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 85.5 - 86 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H14N2O
Molecular Weight: 202.26

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids, strong reducing agents, acid chlorides.
Hazardous Decomposition Products:
Hydrogen cyanide, carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 37812-51-4: XV1050000 LD50/LC50:
Not available.
Carcinogenicity:
4-(Morpholinomethyl)benzonitrile - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.*
Hazard Class: 8 (6.1)
UN Number: 2923
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.
Hazard Class: 8 (6.1)
UN Number: 2923
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, TOXIC, N.O.S.
Hazard Class: 8 (6.1)
UN Number: 2923
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 34 Causes burns.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 37812-51-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 37812-51-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 37812-51-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4-吗啉基甲基)苯腈 在 二异丁基氢化铝 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以46%的产率得到4-吗啉甲基苯甲醛
  参考文献：
  名称：

  使用基于片段的方法开发脓肿分枝杆菌 tRNA (m1G37) 甲基转移酶 (TrmD) 抑制剂。

  摘要：

  脓肿分枝杆菌 (Mab) 是一种快速增长的多重耐药非结核分枝杆菌，对囊性纤维化和其他已有慢性肺部疾病的患者构成越来越大的威胁。单克隆抗体肺部感染很难治疗，有时甚至不可能治疗，会导致肺功能加速衰退和过早死亡。因此，迫切需要开发具有改善功效的新型抗生素。tRNA (m1G37) 甲基转移酶 (TrmD) 是新型抗生素的一个有前景的靶标。它对于 Mab 和其他分枝杆菌至关重要，可改善核糖体上的读码框维护以防止移码错误。在这项工作中，采用基于片段的方法，合并与活性位点结合的两个片段，然后进行结构引导的精加工，以设计针对 Mab TrmD 的有效纳摩尔抑制剂。其中几种化合物对分枝杆菌物种表现出有希望的活性，除了 Mab 之外，还包括结核分枝杆菌和麻风分枝杆菌，支持使用 TrmD 作为开发抗分枝杆菌化合物的靶点。

  DOI：

  10.1021/acs.jmedchem.9b00809
• 作为产物：
  描述：

  对氰基溴化苄 以72的产率得到4-(4-吗啉基甲基)苯腈
  参考文献：
  名称：

  Anti-malarial agents

  摘要：

  本发明涉及一种新型的喹诺酮-4-羧酰胺Pf3D7抑制剂，其通式为(I)（式(I)）其中R1、R2、R3、R4、R5、R6、R7、R8和X如本文所定义，以及它们在医学上的使用，特别是在疟疾治疗中的使用，包含它们的组合物，用于它们的制备过程和用于这样的过程中的中间体。

  公开号：

  US09115088B2

文献信息

• Regioselective Borylation of the C–H Bonds in Alkylamines and Alkyl Ethers. Observation and Origin of High Reactivity of Primary C–H Bonds Beta to Nitrogen and Oxygen
  作者：Qian Li、Carl W. Liskey、John F. Hartwig

  DOI：10.1021/ja503676d

  日期：2014.6.18

  Borylation of aliphatic C-H bonds in alkylamines and alkyl ethers to form primary aminoalkyl and alkoxyalkyl boronate esters and studies on the origin of the regioselectivity of these reactions are reported. The products of these reactions can be used directly in Suzuki-Miyaura cross-coupling reactions or isolated as air-stable potassium trifluoroborate salts. Selective borylation of the terminal C-H

  报道了烷基胺和烷基醚中脂肪族 CH 键的硼化反应，形成伯氨基烷基和烷氧基烷基硼酸酯，并研究了这些反应的区域选择性起源。这些反应的产物可直接用于 Suzuki-Miyaura 交叉偶联反应或作为空气稳定的三氟硼酸钾盐分离。位置 β 的末端 CH 键选择性硼化为氧和氮，优先于其他末端 CH 键的硼化。实验研究和计算结果表明，CH 键断裂是当前硼化反应的速率决定步骤。在乙胺和醚的末端位置观察到的 CH 键的更高反应性是由于有吸引力的路易斯酸碱和氢键相互作用的结合，以及过渡态中典型的排斥性空间相互作用。在这种过渡态中，杂原子直接位于一个硼基配体的硼原子上方，在弱路易斯酸和路易斯碱之间产生稳定的相互作用，并且底物的一系列 CH 键位于硼基配体的氧原子附近，参与一组弱的 CH···O 相互作用，导致形成主要产物的过渡态显着稳定。
• [EN] ANTIMALARIAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIPALUDIQUES
  申请人：LIVERPOOL SCHOOL TROPICAL MEDICINE

  公开号：WO2012069856A1

  公开（公告）日：2012-05-31

  The present invention relates to antimalarial compounds. More specifically, the present invention relates to novel substituted quinolone derivatives of formula (I) and related quinoline derivatives of formula (II) as defined herein that possess potent antimalarial activity. The present invention also relates to processes for the preparation of these quinolone and quinoline derivatives, to pharmaceutical compositions comprising them and to their use as therapeutic agents for the treatment and/or prevention of malaria.

  本发明涉及抗疟疾化合物。更具体地，本发明涉及具有强效抗疟活性的本发明中定义的新型取代喹诺酮衍生物（式（I））和相关喹啉衍生物（式（II））。本发明还涉及制备这些喹诺酮和喹啉衍生物的方法，包括含有它们的药物组合物以及它们作为治疗和/或预防疟疾的治疗剂的用途。
• Highly efficient Amination in Neat Water of Benzyl Chlorides with Dialkylformamides Catalysed by <i>N</i>-Heterocyclic Carbene-Palladium(II)-1-Methylimidazole Complex
  作者：Wen-Xin Chen、Cai-Yun Zhang、Jian-Mei Lu

  DOI：10.3184/174751913x13787959859344

  日期：2013.10

  Dialkylformamides are excellent N-sources in the amination of benzyl chlorides when catalysed by a NHC-Pd(II)-Im complex. In the presence of NaOH and the catalyst, variously substituted benzyl chlorides and five different dialkylformamides reacted smoothly to afford the corresponding N,N-dialkyl-benzylamines in good to almost quantitative yields in eco-friendly solvent water at 50 °C within 3 h.

  当由 NHC-Pd(II)-Im 复合物催化时，二烷基甲酰胺是苄基氯胺化过程中极好的 N 源。在 NaOH 和催化剂存在下，不同取代的苄基氯和五种不同的二烷基甲酰胺在 50°C 的环保溶剂水中顺利反应，在 3 小时内得到相应的 N,N-二烷基-苄胺，产率几乎是定量的。
• Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition
  作者：Waleed H. Malki、Ahmed M. Gouda、Hamdy E.A. Ali、Rabaa Al-Rousan、Doaa Samaha、Ashraf N. Abdalla、Juan Bustamante、Zakaria Y. Abd Elmageed、Hamed I. Ali

  DOI：10.1016/j.ejmech.2018.04.029

  日期：2018.5

  Protein kinases are promising therapeutic targets for cancer therapy. Here, we applied multiple approaches to optimize the potency and selectivity of our reported alloxazine scaffold. Flexible moieties at position 2 of the hetero-tricyclic system were incorporated to fit into the ATP binding site and extend to the adjacent allosteric site and selectively inhibit protein kinases. This design led to

  蛋白激酶是癌症治疗的有希望的治疗靶标。在这里，我们应用了多种方法来优化我们报道的阿洛嗪支架的效价和选择性。杂三环系统位置2的柔性部分被纳入以适合ATP结合位点，并延伸到相邻的变构位点，并选择性抑制蛋白激酶。这种设计导致对ABL1，CDK1 / Cyclin A1，FAK和SRC激酶的潜在选择性抑制作用达到30-59％。优化的铅（10b； IC50 = 40 nM）对乳腺癌（MCF-7）细胞的细胞毒性提高了约50倍。许多化合物显示出对卵巢（A2780）和结肠癌（HCT116）细胞潜在的细胞毒性，可提高约10-30倍（IC50 5-17 nM）。膜联蛋白-V / PI凋亡测定的结果表明，与MCF-7细胞的媒介物对照相比，许多化合物可诱导明显的早期死亡（89-146％）和显着晚期的（556-1180％）细胞死亡。SAR表明，5-脱氮杂恶嗪比Alo-1和FAK激酶具有更高的选择性。GoldScor
• Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors
  作者：Richard J. R. Elliott、Ashley Jarvis、Mohan B. Rajasekaran、Malini Menon、Leandra Bowers、Ray Boffey、Melanie Bayford、Stuart Firth-Clark、Rebekah Key、Rehan Aqil、Stewart B. Kirton、Dan Niculescu-Duvaz、Laura Fish、Filipa Lopes、Robert McLeary、Ines Trindade、Elisenda Vendrell、Felix Munkonge、Rod Porter、Trevor Perrior、Caroline Springer、Antony W. Oliver、Laurence H. Pearl、Alan Ashworth、Christopher J. Lord

  DOI：10.1039/c5md00210a

  日期：——

  The tankyrase proteins (TNKS, TNKS2) are attractive anti-cancer drug targets, particularly as inhibition of their catalytic activity has been shown to antagonise oncogenic WNT signalling.

  坦克酶蛋白（TNKS，TNKS2）是具有吸引力的抗癌药物靶点，特别是因为已经显示抑制它们的催化活性可以对抗致癌的WNT信号传导。